Publications
CAR T Cells
G-Rex®6M – 2cm² Well Plate
Publication Date: June 1, 2026
An 11-day CAR T-cell process originally run in standard tissue culture vessels was transferred to the G-Rex® platform at research scale, giving a satisfactory yield of CAR T-cells with similar phenotype and function. The product was a third-generation anti-CD19 CAR carrying CD28 and TLR2 co-stimulatory domains. With donor 1 cells, manual, Cocoon automated and G-Rex® runs each achieved over 30-fold expansion, with consistent CAR19 expression and CD4/CD8 ratios. The process was then shortened to 7 days in G-Rex® 2 cm² plates using cells from four donors. These products were enriched for stem-cell-like and central memory subsets, showed balanced CD4/CD8 ratios and limited exhaustion marker e…
Publications
CAR T Cells
Publication Date: June 1, 2026
FDA's draft guidance explains how developers of human gene therapy products that incorporate genome editing can reuse existing public and platform knowledge to cut the data they must newly generate. It covers chemistry, manufacturing and controls, nonclinical and clinical areas. Leveraging knowledge may expedite development, particularly for genome editing products. For manufacturing, examples include platform analytical methods, lot release specifications, stability, comparability and process validation data, where reduced numbers of process performance qualification batches may be justified. For nonclinical work, off-target data are generally not appropriate to leverage across products…
Publications
CAR T Cells
G-Rex®500M-CS
Publication Date: June 1, 2026
Miltenyi Biotec reports that the CliniMACS Prodigy can act as the controlling hub of a hybrid, functionally closed manufacturing process in which expansion takes place in an external G-Rex® 500M-CS vessel. In a case study, CD19/CD20 CAR T cells were enriched, activated and transduced on the Prodigy, moved on Day 5 into G-Rex® 500M-CS devices filled to 5 L, and harvested automatically on Day 12 by a custom program. Expansion matched the internal CentriCult Unit culture. Naive and central memory frequencies were 85.8% for CD4 and 93.5% for CD8 cells, against 88.5% and 93.2% in the control. Both cultures killed over 90% of target cells at a 10:1 E:T ratio after 48 hours.
Publications
CAR T Cells
Publication Date: May 15, 2026
Activating and transducing T cells with the Syenex RapidCell engineered vector produced a CD19-targeting CAR T product while removing separate selection and activation-reagent steps, cutting estimated cost of goods by about 55%. Across leukopaks from several donors, CD3+ purity at harvest exceeded 95%, and mean CAR positivity reached 77.6% and 79.63% at MOI 0.2 and 2.0, versus 28.92% for the historical lentiviral process. T-cell expansion stayed within about 10% of that process, and harvest viability was above 88%. Processing time fell by roughly 40%. Interferon-gamma release reached about 10^5 pg/mL, and the estimated number of doses per batch rose from 4 to 11.
Publications
TCR T Cells
G-Rex®100M, G-Rex®6M – 2cm² Well Plate
Publication Date: May 15, 2026
A 10-day manufacturing protocol for KRAS G12D-targeting TCR-T cells, using a cytokine cocktail of IL-2, IL-7, IL-15 and TGF-β, produced products richer in early memory and tissue-resident-like cells than IL-2 alone. Cocktail-made cells showed higher 4-1BB upregulation and greater IFN-γ, TNF and granzyme B secretion, and killed pancreatic and colorectal tumor cell lines more effectively in 2D and 3D cultures. Patient-derived CD8-enriched cells were transduced retrovirally. At clinical scale, 1.2 × 10^9 PBMC were stimulated and expanded in G-Rex® 100M flasks. Two runs gave 3.30 and 6.15 × 10^9 cells, with 86% and 85% transduction efficiency, and similar phenotype and function.
Publications
CAR T Cells
G-Rex®500M
Publication Date: May 12, 2026
An automated, closed workflow for CAR T manufacturing produced comparable, high-quality products across scales. Four processes were run in triplicate on three donors: three on the CliniMACS Prodigy and one on the CliniMACS Plus with a G-Rex® 500M. Cells were activated, transduced with a CD19 lentiviral vector at MOI 5 on Day 1, and harvested on Day 7. Viability was 95% to 98%. Yields reached about 3×10⁸ cells in the core process and up to 2×10¹⁰ in the large-scale configuration. Agitated cultures showed stronger activation and higher vector copy numbers. All products were memory-dominated with low exhaustion markers and killed Raji cells, with up to 80–95% lysis at 48 hours.
Publications
Other
Publication Date: May 5, 2026
FDA describes how it applies flexibility to chemistry, manufacturing, and controls requirements for cellular and gene therapy products developed for biologics license applications. During clinical development, it encourages phase-appropriate GMP and release criteria, risk-based comparability studies, and leveraging prior knowledge. For process validation, FDA sets no minimum number of process performance qualification batches and may allow concurrent release of such batches after approval. For commercial specifications, it may accept flexible release specifications when few lots exist and analytical validation on a single representative lot. It also recommends real-time stability data fro…
Publications
Other
Publication Date: May 1, 2026
This FDA guidance, issued in May 2026 as revision five of the ICH Q8, Q9, and Q10 Questions and Answers, clarifies how pharmaceutical development, quality risk management and the pharmaceutical quality system are applied in practice. It states that establishing a design space or using real time release testing is not necessarily expected under Quality by Design. It explains that a control strategy is required for all products, that real time release testing does not necessarily eliminate all end product testing, and that a stability monitoring protocol is required regardless of the release approach. It also says no ICH Q10 certification program exists and that firms need not buy software…
Publications
Other, γδ T
G-Rex®10M-CS
Publication Date: April 21, 2026
Tumor-reactive T cells targeting PRAME, Survivin and WT1 can be manufactured to clinical grade on the automated, closed CliniMACS Prodigy platform, using cells from antigen-naïve healthy donors and from pediatric transplant recipients. In three full-scale donor runs, CD137-selected cells expanded to 81.9–1,963 × 10⁶ viable CD3⁺ cells within 10–12 days. Scaled-down runs from two transplant recipients, with manual enrichment and closed-system expansion, reached 20.4–49.5 × 10⁶ viable CD3⁺ cells over 14 days. All final products met release criteria for sterility, endotoxin and mycoplasma and showed antigen-specific cytokine and activation-marker responses. Products were also rich in γδ T cel…
Publications
Treg Cells
G-Rex®10, G-Rex®100
Publication Date: April 9, 2026
Human regulatory T cells (Tregs) in which the FKBP1A gene was knocked out by CRISPR-Cas9 ribonucleoprotein editing kept their Treg phenotype and suppressive function while becoming resistant to tacrolimus, yet stayed sensitive to cyclosporine A. Editing efficiency reached roughly 60% with high-fidelity Cas9 and 80% with standard Cas9 after 21 days of expansion. Under tacrolimus, edited cells proliferated better and suppressed FKBP12-knockout effector cells more strongly than unedited Tregs. Off-target analysis of 255 prioritized sites found four with significant editing, all variants of unknown significance. Three GMP validation runs gave 94–95% viability, 95–97% CD4+CD25+FOXP3+ cells and…
Publications
CAR T Cells
Publication Date: April 7, 2026
Treating CRISPR-engineered GD2 TRAC-CAR T cells with the class I HDAC inhibitor chidamide enhanced their stem-like memory features and, in mice, their persistence. CAR T cells with a GD2 CAR inserted into the TRAC locus were thawed, rested for 24 h and exposed to five HDAC inhibitors for 72 h. Chidamide and mocetinostat raised co-expression of CD62L, CCR7 and IL-7Rα by over 80% relative to untreated cells, while cytotoxicity against CHLA-20 neuroblastoma cells was largely preserved. Chidamide fragmented mitochondria. In a neuroblastoma xenograft in NRG mice, splenic CAR+/TCR− cells were 14.8-fold higher than with mocetinostat, and the stem-memory fraction was 4-fold higher than untreated.…
Publications
T-Cells
G-Rex®10
Publication Date: March 21, 2026
A fully contained, automated cytokine release assay using primary human CD4+ T cells was built to support medium- to high-throughput compound screening. Purchased CD4+ T cells are activated with anti-CD3/CD28 beads for 3 days, then expanded in a G-Rex® 10 flask to reach a 6- to 8-fold increase by day 7. One vial of 1.5E7 cells supplies roughly 3,000 assay wells. Cells are dispensed at 30,000 per well into 384-well plates with compound, restimulated with ImmunoCult, and IL-2 in the supernatant is read by HTRF after 20 to 24 hours. The assay generated more than 5,600 IC50 curves and 11,000 single-dose datapoints with Z primes above 0.2, and supported discovery of an ITK inhibitor clinical c…
No manuscripts match your filters.